The latest generic entry comes on the heels of a new report from ICER, which published a list of prescription drugs that had substantial price increases in 2017 and 2018 without what they consider to be new supporting evidence.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Fred Rincon, MD, MSc.
New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.
With a growing emphasis on early detection and intervention, the American Academy of Neurology (AAN) has published a new set of quality measurements that recommend that physicians screen adults 65 and older on an annual basis for thinking
The phase 3 clinical trial program included 2 identical, multicenter, double-blind, and placebo-controlled trials of the BACE inhibitor intended for the treatment of early Alzheimer disease.
Rodney Allan Radtke, MD, professor of neurology at Duke University School of Medicine in Durham, North Carolina, discussed some of the new therapeutic options available to help improve tolerance and adherence challenges that clinicians commonly face in epilepsy practice.
Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Reisa Sperling, MD.
The review is an update to a drug safety communication initially issued in 2010 after trial results suggested a possible increased risk for prostate cancer with use of entacapone.
The International Congress on the Future of Neurology will take place this Fall in New York City, convening experts in neurology to discuss the latest data and best practices to better inform clinical decision-making.